Last reviewed · How we verify
NCT05556395
Global Blood-Brain Barrier Disruption and Post-Stroke Cognitive Decline
trial in Ischemic Stroke in 150 participants. Currently enrolling.
1 April 2027
Quick facts
| Lead sponsor | Johns Hopkins University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 1 April 2022 |
| Primary completion | 1 April 2027 |
| Estimated completion | 1 April 2027 |
| Sites | 1 location across United States |
Conditions studied
- Ischemic Stroke — all drugs for Ischemic Stroke →
Sponsor
Johns Hopkins University
Who can join
18 and older, any sex, with Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to gain a better understanding of why some individuals who have suffered a stroke experience post-stroke cognitive decline. Specifically this study is testing whether global disruption of the blood-brain barrier detected at the time of the stroke is informative about the risk of post-stroke cognitive decline over the next 3 years.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Restoring brain barriers: an innovative approach for treating neurological disorders.
Lemarchant S, Engelhardt B, Cicchetti F, Bix GJ, et al · · 2025 · cited 5× · PMID 40640916 · DOI 10.1186/s12987-025-00688-z
Verify or expand the search:
- PubMed search for NCT05556395
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ischemic Stroke
Currently open trials in the same condition.
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
- NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
- NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
- NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting
Other Johns Hopkins University trials
Trials by the same sponsor.
- NCT06236542 — Tracheostomy Robotics and Cutting-edge Health Education for Airway Safety · NA · not yet recruiting
- NCT07532252 — Daridorexant for Alcohol Use Disorder · Phase 2 · not yet recruiting
- NCT06687655 — Impact of Exogenous Ketones on Sleep Apnea · Phase 1, PHASE2 · not yet recruiting
- NCT07079111 — 3D Printed Occlusal Splints for Intraoperative Use · NA · not yet recruiting
- NCT02998502 — The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05556395 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins University
- Last refreshed: 29 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05556395.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing